Characterizing the Extended Language Network in Individuals with Multiple Sclerosis - Ratzan, Alexander S.; Simani, Leila; Dworkin, Jordan D.; Buyukturkoglu, Korhan; Riley, Claire S.; Leavitt, Victoria M. (medRxiv, 2025)
Background Language dysfunction is increasingly recognized as a prevalent and early affected cognitive domain in individuals with MS.Objectives To establish a network-level model of language dysfunction in MS.Methods Cognitive data and 3T functional and structural brain MRI were acquired from 54 MS patients and 54 matched healthy controls (HCs). Functional summary measures (anteriority, segregation, betweenness, within-ness) of the extended language network (ELN) were calculated and structural imaging metrics were derived. Group differences in ELN connectivity were evaluated. Associations between ELN connectivity and language performance were assessed; in the MS group, an unsupervised learning approach was used to assess relationships between multimodal neuroimaging features derived from language-related areas and performance on language tasks.Results The MS group performed worse on semantic fluency and rapid automized naming tests (p<0.005) compared to HC. Regarding ELN measures, the MS group exhibited higher within-ELN connectivity than HCs (p<0.05). Principal component analysis (PCA) yielded a multimodal latent component that uniquely correlated with language performance (p<0.05).Conclusion We identified network-level functional and structural measures to potentially characterize language dysfunction in MS. Further studies leveraging these features may reveal mechanisms and predictors of language dysfunction specific to MS.Competing Interest StatementDisclosure: VML has been compensated for advisory or consulting services by the following entities in the last year: Novartis, Biogen. CSR has been compensated for advisory or consulting services by the following entities in the last year: EMD Serono, TG Therapeutics, Horizon, Novartis, Viracta, Genentech. ASR has nothing to disclose. JDD has nothing to disclose. KB has nothing to disclose.LS has nothing to disclose.Funding StatementThis study was funded by the United States Department of Defense Congressionally Directed Medical Research Program (W81XWH-20-1-0503). Grant funding to Yaakov Stern supported the RANN cohort (RF1AG038465).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Columbia University Medical Center gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in this study are available upon request to the corresponding author.